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ABSTRACT: Antibodies are indispensable tools in biomedical
research, but their size, complexity, and sometimes lack of
reproducibility created a need for the development of
alternative binders to overcome these limitations. Aﬃmers are
a novel class of aﬃnity binders based on a structurally robust
protease inhibitor scaﬀold (i.e., Cystatin A), which are selected
by phage display and produced in a rapid and simple E. coli
protein expression system. These binders have a deﬁned amino
acid sequence with deﬁned binding regions and are versatile,
thereby allowing for easy engineering. Here we present an
aﬃmer-based liquid chromatography−mass spectrometry (LC−
MS) method for quantiﬁcation of the soluble Receptor of
Advanced Glycation End-products (sRAGE), a promising
biomarker for chronic obstructive pulmonary disease. The method was validated according to European Medicines Agency
and U.S. Food and Drug Administration guidelines and enabled quantitation of serum sRAGE between 0.2 and 10 ng/mL.
Comparison between the aﬃmer-based method and a previously developed, validated antibody-based method showed good
correlation (R2 = 0.88) and indicated that 25% lower sRAGE levels are reported by the aﬃmer-based assay. In conclusion, we
show the ﬁrst-time application of aﬃmers in a quantitative LC−MS method, which supports the potential of aﬃmers as robust
alternatives to antibodies.
KEYWORDS: aﬃmers, biomarker, COPD, immunoprecipitation, LC−MS, quantiﬁcation
■ INTRODUCTION
Antibodies have found numerous applications in present-day
biomedical research owing to their capability of binding
antigens with high aﬃnity and speciﬁcity. These aﬃnity
reagents are, for example, widely used for the enrichment of
target molecules, the detection of target molecules, and the
analysis of cells.1 Antibodies have furthermore become well-
rooted in clinical practice, as exempliﬁed by the more than 60
therapeutic antibodies reaching the market since the ﬁrst
therapeutic antibody, Muromonab-CD3, received regulatory
approval from the United States (U.S.) Food and Drug
Administration (FDA) in 1986.2
The possibilities and importance of antibodies are beyond
dispute, although these proteins are not without their
limitations.2 For example, antibodies are large and complex
proteins with a molecular weight around 150 kDa featuring
several disulﬁde bonds and N-glycosylated asparagine
residues.3 Antibody production accordingly is a challenging
and costly process. Their production is furthermore diﬃcult to
control, as reﬂected in an increasing number of reports
describing reproducibility issues.2−5 Consequently, consider-
able eﬀorts have been expended in recent years to develop
nonantibody aﬃnity ligands, which resulted in an impressive
number of putative antibody alternatives, including adnectins,
aﬃbodies, anticalins, avimers, DARPins, fynomers, knottins,
and kunitz domains.2,6 Aﬃmers that are derived from the
cysteine protease inhibitor Cystatin A represent another
example of antibody alternatives. These innovative aﬃnity
ligands can be produced quickly, relatively easily, and without
the use of animals. Aﬃmers are small, versatile, and stable
proteins that can be engineered to bind target proteins with
high aﬃnity and selectively.6 Their eﬃciency of binding linear
targets (e.g., peptides) is, however, limited. Moreover,
examples of their application are still limited in number
because aﬃmer technology has only been established recently,
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although the few available examples do indicate that aﬃmers
represent attractive alternatives to antibodies, at least for some
applications.7−15
Recently, we reported on the development and validation of
an antibody-based immunoaﬃnity liquid chromatography−
mass spectrometry (LC−MS) method for quantiﬁcation of the
soluble Receptor of Advanced Glycation End-products
(sRAGE) in human serum.16 sRAGE has anti-inﬂammatory
properties by acting as a decoy receptor for pro-inﬂammatory
ligands in the lungs and is considered to be a promising
biomarker candidate for chronic obstructive pulmonary disease
(COPD) on the basis of ﬁndings in several large-scale clinical
studies.17−21 In addition, sRAGE is considered to be an
interesting biomarker as well for other diseases including
diabetes mellitus, autoimmune diseases, and neurological
diseases.22 The corresponding ﬁndings are, however, all
based on data obtained with a single sRAGE immunoassay.20
In our initial report on the antibody-based LC−MS method,
we presented data that triggered concerns about the accuracy
of the immunoassay.16 Because our antibody-based LC−MS
method relies on antibodies from the vendor of the sRAGE
immunoassay, we felt the need for complementary, antibody-
free strategies for enriching sRAGE to support the further
development of sRAGE as a biomarker.
In this study, we describe the application of aﬃmers in an
LC−MS method for the quantiﬁcation of sRAGE in human
serum. The aﬃmer-based method met the requirements as
stipulated in the European Medicines Agency (EMA) and
FDA guidelines on bioanalytical method validation,23,24 and its
measurements correlated well with those carried out using a
previously developed antibody-based LC−MS method. The
successful application of aﬃmers in a quantitative sRAGE
method is expected to contribute to further elucidating the role
of sRAGE in COPD pathophysiology and in facilitating further




Recombinant human sRAGE (rh-sRAGE; cat. no. C423;
UniProtKB ID Q15109; Ala23-Ala344 with C-terminal hexa-
histidine tag) was purchased from Novoprotein (Summit, NJ),
anti-sRAGE aﬃmers (raised against recombinant human
sRAGE from Novoprotein, cat. no. C423) were produced
and supplied by Avacta Life Sciences (Wetherby, U.K.), and
stable-isotope-labeled RAGE peptides (i.e., IGEPLVLK* and
VLSPQGGGPWDSVAR*) were synthesized by Pepscan
Presto (Lelystad, The Netherlands). Acetonitrile (ACN;
LC−MS grade) was obtained from Biosolve (Valkenswaard,
The Netherlands), and sequencing grade modiﬁed trypsin was
purchased from Promega (Madison, WI). Nunc-Immuno
MicroWell 96-well plates with MaxiSorp coating (cat. no.
M9410), bovine serum albumin (BSA; cat. no. A7638), Trizma
base (tris; cat. no. T6791), and phosphate-buﬀered saline
(PBS; 10×; cat. no. D1408) as well as all other chemicals were
purchased from Sigma-Aldrich (Zwijndrecht, The Nether-
lands).
Serum Samples
Pooled human serum from Seralab (West Sussex, U.K.) was
diluted with 10 mM tris-buﬀered saline, pH 7.5 (TBS buﬀer)
containing 1% BSA for the preparation of the low-level quality
control (QC-low) sample or was fortiﬁed with recombinant
RAGE at two levels to obtain the midrange (QC-medium) and
high-level (QC-high) quality-control samples. Recovery and
spike recovery experiments were carried out using six diﬀerent
sources of human serum from healthy subjects (all from
Seralab). Recovery and spike recovery experiments were
furthermore performed on a lipemic serum sample (trigly-
ceride content >150 mg/dL; obtained from Seralab) and a
hemolytic sample that was prepared by adding freeze−thawed
whole blood (2%) to human serum.
Calibrants and Internal Standard
Lyophilized sRAGE was dissolved in Milli-Q water to obtain a
200 μg/mL solution (based on the quantity as declared by the
supplier) that was diluted to 100 μg/mL with 1× PBS, pH 7.4
(PBS buﬀer) after verifying the absence of proteins other than
sRAGE using SDS-PAGE and MALDI-TOF MS. The resulting
solution was sequentially diluted to 100 ng/mL with 1% BSA
in TBS buﬀer (Surrogate Matrix), and calibration samples were
prepared at 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 8.0, and 10.0 ng/mL in
Surrogate Matrix. The internal standard (IS) stock solution
was prepared by mixing equimolar amounts of the two SIL-
peptides (supplied as 5 pmol/μL solutions in 5% ACN) and
subsequently diluting these peptides to 5 fmol/μL with 1%
dimethyl sulfoxide (DMSO) in water.
Aﬃmer-Based sRAGE Capture and In-Well Digestion
(1) Plate Coating: Microplate wells were coated overnight
(room temperature) with 100 μL of PBS buﬀer containing 0.5
μg of the aﬃmers B7 and G10. (Aﬃmers were supplied as 1
mg/mL solutions in citrate-buﬀered saline, pH 6.5 containing
5 mM TCEP and 0.02% sodium azide.) (2) Plate Blocking:
After removal of unbound aﬃmers by three washing steps with
300 μL of wash buﬀer (0.05% Tween-20 in TBS buﬀer),
uncoated surface was blocked with 300 μL of blocking buﬀer
(0.01% BSA in TBS buﬀer) for 30 min while shaking on a plate
shaker (600 rpm; room temperature). (3) sRAGE Capture:
Wells were washed three times with 300 μL of wash buﬀer, and
100 μL of sample solution (for which 60 μL of serum was
premixed with 60 μL of Surrogate Matrix to allow quantitative
transfer of Sample Solution) was added to the wells for the
capture of sRAGE (120 min; 600 rpm; room temperature). (4)
Disulﬁde Bond Reduction: After three washing steps with 300
μL of wash buﬀer, 100 μL of digestion buﬀer (50 fmol/mL
SIL-peptides in 50 mM ammonium bicarbonate (ABC)
containing 10 mM TCEP) was added to the wells, and
disulﬁde bonds were reduced following 30 min of incubation
(600 rpm; room temperature). (5) Cysteine Alkylation: Thiols
were alkylated in 20 mM iodoacetamide (IAM) (5 μL of 420
mM IAM in ABC) for 30 min in the dark (600 rpm; room
temperature), after which nonreacted IAM was quenched with
a 0.5 molar excess of DTT (5 μL of 210 mM DTT in ABC).
(6) Trypsin Digestion: 100 ng of trypsin was added to each
sample, plates were sealed with a 96-well cap mat (Screening
Devices B.V., cat. no. SD964075), and proteins were digested
following overnight incubation in an oven kept at 37 °C. Next,
plates were brieﬂy centrifuged in a plate centrifuge to spin
down droplets and condensation, and the digests were acidiﬁed
through the addition of 5 μL of 25% formic acid (FA).
LC−MS
Analyses were performed with a Waters Ionkey/MS system
using an ACQUITY M-Class UPLC and a XEVO TQ-S mass
spectrometer (Milford, MA). Chromatographic separation was
achieved on a C18-bonded Waters iKey HSS T3 separation
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device (1.8 μm particles, 100 Å pore size, 150 μm × 100 mm;
cat. no. 186007261) that was kept at 40 °C using 0.1% FA in
H2O as mobile phase A and 0.1% FA in ACN as mobile phase
B. Twenty μL of sample was loaded onto a Dionex Acclaim
PepMap100 C18 trap column (5 μm particles, 100 Å pore size,
300 μm × 5 mm; cat. no. 160454) for 2.5 min with 3% B at 20
μL/min. Subsequently, peptides were separated on the
analytical column at 3 μL/min with a 10 min linear gradient
from 3 to 33% B, after which the column was cleaned (0.6 min
at 60% B and 2.1 min at 95% B) and equilibrated (4.3 min at
3% B). Mass spectrometric detection was performed using the
following conditions: ESI positive, precursor ion and fragment
ion windows at unit mass resolution (0.7 amu), span 0.2,
capillary voltage 3.5 kV, cone voltage 30 V, source oﬀset 50 V,
source temperature 120 °C, cone gas (nitrogen) ﬂow 150 L/h,
sheath (nanoﬂow) gas (nitrogen) ﬂow 0.2 bar, and collision
gas (argon) ﬂow 0.15 mL/min. MRM transitions and settings
for IGEPLVLK (selected for quantiﬁcation) and VLSPQG-
GGPWDSVAR (selected for conﬁrmation) are presented in
Table S-1. The Ionkey/MS system was operated under the
Waters MassLynx software suite (version 4.1), and the
TargetLynx module of this package was used for data
processing.
Method Validation
The method was validated according to EMA and FDA
guidelines, and the following criteria were addressed: selectivity
(e.g., spike recovery and ligand challenge tests), accuracy and
precision, recovery, calibration curve, and stability (e.g., 28
days benchtop, 10× freeze−thaw, and 13 days autosampler (10
°C)).23,24 For the recovery experiment, samples were fortiﬁed
with 5 ng/mL sRAGE either before or after sRAGE capture to
obtain the precapture and postcapture spiked samples,
respectively. The sRAGE dilutions for the recovery experiment
were prepared in 50 mM ABC because adding Surrogate
Matrix to the postcapture spiked samples would introduce
excessive BSA to the samples, thereby interfering with
digestion and LC−MS analysis. sRAGE in Surrogate Matrix
was used for the spike-recovery experiments, and the
corresponding spiking procedure was similar to that of the
precapture spiked samples of the recovery experiment. Ligand
challenge tests were performed by adding 200 ng of fully
reduced HMGB1 (HMGBiotech, Milano, Italy; cat. no. HM-
116), S100A12 (Novoprotein; cat. no. C743), serum amyloid
A1 (SAA1; Novoprotein; cat. no. C633), and Nε-
(carboxymethyl)lysine-modiﬁed bovine serum albumin
(CML-BSA; Academy Bio-Medical, Houston, TX; cat. no.
30P-CML-BS102) to the samples. For recovery and selectivity
experiments, samples were incubated for at least 30 min
following the addition of sRAGE or the ligands prior to
initiating sRAGE capture.
Method Comparison
For method comparison, 40 serum samples were analyzed from
a cross-sectional study (NCT00807469) within the University
Medical Center Groningen (UMCG).25 Ethical approval for
this study has been granted by the UMCG’s review board
(METc 2008/136), and the study adheres to the Declaration
of Helsinki. Blood samples were collected as previously
described.16 In all 40 samples, sRAGE was quantiﬁed using
the aﬃmer-based sRAGE assay as well as with the previously
described antibody-based sRAGE assay.16
■ RESULTS AND DISCUSSION
Aﬃmer-Based sRAGE Enrichment
The aﬃmers were supplied with an added C-terminal cysteine
residue (see Figure 1) which allows coupling of the aﬃmers to
Figure 1. Amino acid sequence of the aﬃmer scaﬀold in which the added C-terminal cysteine residue and a hexahistidine tag as well as the
sequences of the inserted loops relevant for sRAGE binding are indicated.
Figure 2. Performance evaluation of the individual aﬃmers A11, B7, and G10 (indicated as A, B, and G, respectively) as well as all aﬃmer
combinations based on the enrichment of endogenous sRAGE or recombinant human sRAGE (rh-sRAGE) from 1% BSA in TBS (BSA) and
human serum, which contained endogenous sRAGE at a level of ∼1 ng/mL. The Figure shows the mean relative peak areas (plus standard
deviations; N = 3) of the proteotypic sRAGE peptides IGEPLVLK (in black; selected as quantiﬁer peptide) and VLSPQGGGPWDSVAR (in gray;
selected as qualiﬁer peptide due to its deamidation-sensitive “QG” sequence motive and due to a single nucleotide polymorphism leading to the
substitution of the C-terminal arginine by a cysteine (e.g., rs116828224) occurring in 0.6% of the population).
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maleimide-activated solid supports (e.g., microtiter plates,
magnetic beads) through the formation of stable thioether
bonds, thus allowing for controlled orientation for a capture
surface. Initially, the performance of the three aﬃmers, A11,
B7, and G10, was assessed on the basis of recombinant human
sRAGE (rh-sRAGE) spiked into saline-based buﬀers (e.g.,
PBS, TBS) at high concentrations (0.1 to 1 μg/mL) and by
using maleimide-activated microtiter plates (Thermo Fisher
Scientiﬁc, cat. no. 15150) or magnetic beads (Cube Biotech,
cat. no. 51201) according to the manufacturer’s instructions.
When aﬃmer performance testing was extended to more
complex samples (e.g., 1% BSA in TBS, serum) fortiﬁed with
rh-sRAGE, it was observed that an increased matrix complexity
led to decreased signals for rh-sRAGE. Speciﬁcally, the relative
peak areas for two sRAGE peptides (see data for rh-sRAGE in
Figure 2) were around 10 times lower than expected based on
samples containing the same amount of sRAGE spiked in
buﬀer only. In addition, it was found that the individual
aﬃmers were incapable of enriching endogenous sRAGE from
serum. (See the data for nonspiked serum and the individual
aﬃmers in Figure 2.) However, endogenous sRAGE was
successfully enriched when combining the B7 aﬃmer with at
least one of the two other aﬃmers. (See the data for nonspiked
serum and the aﬃmer combinations in Figure 2.)
We hypothesized that the B7 aﬃmer may “unveil” the
binding sites of the other two aﬃmers and furthermore
reasoned that the observed extraction diﬀerences for
endogenous and recombinant sRAGE may be due to diﬀerent
ligands being bound to these proteins. Diﬀerences in ligand
binding may, for example, be explained by varying N-glycans
on asparagine residues 25 and 81 of sRAGE, which are
proposed to determine the ligands to which sRAGE will
bind.26 Alternatively, it could be possible that one aﬃmer alone
does not bind endogenous sRAGE strongly enough to extract
it from the complex environment of serum comprising
numerous sugars, lipids, electrolytes, metabolites, and proteins.
Minor structural diﬀerences between the binding sites of
endogenous and recombinant sRAGE may in such a case
represent a plausible explanation for the varying extraction
behaviors that we observed, thereby pointing to a general
diﬃculty when using recombinant proteins as surrogates for
the corresponding endogenous proteins. It is also possible that
the aﬃmers used in combination create an avidity eﬀect, thus
increasing binding eﬃciency by targeting discontinuous
conformational epitopes of sRAGE. To rule out any batch-
speciﬁc eﬀect, we requested the production of a second batch
of aﬃmers, which conﬁrmed the need for using a combination
of aﬃmer B7 with one of the other two aﬃmers.
Corresponding experiments furthermore revealed excellent
batch-to-batch consistency for the aﬃmers’ eﬀectiveness in
enriching sRAGE from serum. (See Figure S-1.) With respect
to the aﬃmer binding sites, we aimed to provide an estimate of
their locations by means of epitope slicing and epitope
extraction experiments for which we used the proteases trypsin
and GluC. However, we were unable to map any of the aﬃmer
binding sites, which suggests the presence of conformational
binding sites. In addition, in other experiments, we observed
that sRAGE could not be enriched from samples that were
acidiﬁed and subsequently neutralized, which hints at
conformational binding sites as well.
We evaluated the aﬃmers’ performance in a quantitative
workﬂow for serum sRAGE by coating the best performing
aﬃmer combination (i.e., B7 and G10; see Figure 2) on
adsorptive microtiter plates, which represent a more
straightforward alternative to the maleimide-activated solid
supports, by analogy to our antibody-based sRAGE method.16
Thereby, the resulting method can be easily incorporated in
(semi)automated workﬂows that are typically available in
larger clinical laboratories, thus contributing to the clinical
potential of this method. The method was optimized with
respect to aﬃmer coating, sRAGE enrichment, and protein
digestion, resulting in the ﬁnal protocol as outlined in the
Methods section. (See Table S-2 for details.) The resulting
method fulﬁlled all requirements as stipulated in regulatory
guidance documents on bioanalytical method validation. (See
the Method Validation section.)23,24 Still, we acknowledge that
Table 1. Summary of Validation Dataa
aExtensive summary of the validation results is presented in Tables S-3−S-15. bAverage value of measured concentrations during the precision and
accuracy experiments was used as nominal concentration.
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elucidating the mechanism behind the multiaﬃmer require-
ment would be desirable to exploit the aﬃmers to their full
potential. We furthermore acknowledge that calibration
materials for complex analytes such as proteins are potential
sources of bias because it is implausible that one recombinant
protein can adequately represent all diﬀerent forms of the
analyte (so-called “proteoforms” or “protein species”)27,28 that
are present in biological samples.
Quantitative Assay Development
We aimed to develop an alternative for our previously
developed antibody-based sRAGE LC−MS assay and accord-
ingly adopted the same internal standard quantiﬁcation
approach using stable-isotope-labeled (SIL) peptides. The
two peptides we selected for sRAGE quantiﬁcation (i.e.,
IGEPLVLK and VLSPQGGGPWDSVAR) are located in the
N-terminal part of sRAGE and thereby reﬂect the protein
domain to which most sRAGE ligands bind.29,30 Further details
of the selection of the SIL peptides can be found in the
publication of the antibody-based method.16
Aﬃmer titration experiments indicated that 0.5 μg of the
aﬃmers is suﬃcient for the reliable and reproducible
enrichment of endogenous sRAGE across the entire concen-
tration range that is relevant for sRAGE quantiﬁcation in
human serum. (See Figure S-2.) For the preparation of the
calibration curves, we tested 1% BSA in TBS and fetal calf
serum (FCS) as surrogate matrices given that analyte-free,
authentic matrix could not be obtained. The slopes of
calibration curves prepared by spiking recombinant sRAGE
in the BSA-based matrix and in human serum were similar, as
judged from the overlapping 95% conﬁdence intervals. (See
Figure S-3.) The enrichment of sRAGE from FCS was,
however, slightly, yet signiﬁcantly less eﬃcient compared with
serum. (See Figure S-3.) Consequently, the suitability of 1%
BSA in TBS as surrogate matrix was tested further during
method validation. Corresponding spike-recovery experiments
yielded an acceptable bias of ±15% (see the Method
Validation section), and we therefore employed 1% BSA in
TBS as surrogate matrix for the preparation of calibrants by
analogy to our antibody-based sRAGE LC−MS assay.
Method Validation
Table 1 features a concise summary of the validation results,
whereas a full overview is given in Tables S-3−S-15. The
aﬃmer-based LC−MS method for sRAGE quantiﬁcation was
validated according to EMA and FDA guidelines on
bioanalytical method validation.23,24 Accurate quantiﬁcation
of sRAGE was demonstrated for a 1/x weighted linear
calibration model using seven nonzero standards between 0.2
(LLOQ: CV and bias <20%) and 10 ng/mL. (See Tables S-3
and S-4.) We did not reach the LLOQ of our previously
developed antibody-based sRAGE LC−MS method16 (i.e., 0.1
ng/mL) because the 0.1 ng/mL calibration standard in the
third accuracy and precision run deviated too much from the
predicted sRAGE level. (See Table S-16.) This result was the
sole obstacle to demonstrating an LLOQ of 0.1 ng/mL (see
Table S-17), and we therefore did include a summary of the
validation results based on an LLOQ of 0.1 ng/mL in the
Supporting Information. (See Table S-18.) Levels of back-
ground noise were furthermore comparable for both methods,
and peak areas were similar, too, as is exempliﬁed by the
LLOQ selected ion chromatograms presented in Figure 3.
With respect to the required LLOQ, we can state that we did
not observe sRAGE levels below 0.4 ng/mL in ∼1000 samples
from various clinical studies, and we therefore consider that an
LLOQ of 0.2 ng/mL will not aﬀect the applicability of the
aﬃmer-based method.
The evaluation of accuracy and precision revealed acceptable
biases and CVs (within ±15%), which were slightly higher for
the QC-low compared with the QC-medium and QC-high
samples. (See Tables S-5−S-7.) The recovery of the aﬃmer-
based enrichment procedure was high (>90%) and precise
(CVs < 10%) when considering the average of duplicate
measurements as well as when based on the individual
replicates. (See Table S-11.) Furthermore, the assessment of
sample stability after 28 days of storage on the benchtop
Figure 3. Selected ion chromatograms of the y7+ (quantiﬁer), y5+ (qualiﬁer 1), and y6+ (qualiﬁer 2) fragments of the sRAGE-derived proteotypic
peptide IGEPLVLK at 0.1 ng/mL in Surrogate Matrix obtained by (A) the aﬃmer-based method and (B) the antibody-based method.16 The y axes
of the three MRM traces were linked and scaled to the highest observed signal observed in these traces. The presented peak areas represent the
average values for all samples that were measured for the lower limit of quantiﬁcation (LLOQ) determination. No statistically signiﬁcant diﬀerences
(p < 0.05, two-tailed Student’s t test) between both methods were observed for all three fragments.
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(room temperature) and upon 10 freeze−thaw cycles indicated
that sRAGE is a rather stable biomarker based on the sites that
are recognized by the aﬃmers and the proteotypic peptide that
is used for sRAGE quantiﬁcation by LC−MS. (See Tables S-9
and S-10.)
To assess the selectivity of the sRAGE method, spike-
recovery and ligand challenge testing experiments were carried
out. The spike-recovery experiments that included six diﬀerent
sources of serum, a lipemic sample, and a hemolytic sample,
revealed acceptable biases within ±15%. (See Tables S-12 and
S-14.) Ligand challenge testing was performed by fortifying 0.2
ng/mL calibrants with >10 000-times molar excesses of high
mobility group box 1 protein (HMGB1), which is the most
studied and characterized RAGE ligand,31,32 S100 calcium-
binding protein A12 (S100A12), and serum amyloid A1
(SAA1) as examples of damage-associated molecular pattern
(DAMP) proteins known to bind RAGE33,34 or Nε-
(carboxymethyl)lysine-modiﬁed bovine serum albumin
(CML-BSA), which we included as a surrogate for advanced
glycation end-product-modiﬁed proteins.18 Ultimately, none of
the tested ligands aﬀected the measured sRAGE levels. (See
Table S-15.)
Method Comparison
The agreement between the aﬃmer-based LC−MS sRAGE
assay and the previously developed antibody-based LC−MS
sRAGE assay16 was assessed on the basis of 40 clinical samples
using linear regression and Bland−Altman plots. (See Figure
4.) The comparison between both methods revealed good
correlation (R2 = 0.88) but also showed that ∼25% lower
sRAGE levels were reported by the aﬃmer-based assay. Given
that the same sRAGE stock was used for the preparation of the
calibrants for both methods, the observed diﬀerence likely
represents a biology-based bias rather than a calibration-related
artifact. Whereas the reason for this slight bias remains unclear
at present, it is conceivable that the diﬀerent aﬃnity ligands
enrich a diﬀerent subset of sRAGE proteoforms or that sRAGE
molecules bound to speciﬁc sRAGE ligands are enriched with
diﬀerent eﬃciencies by the two methods. Thereby, these data
emphasize the need to diﬀerentiate between sRAGE proteo-
forms and to study the “sRAGE ligandome” to gain a better
insight into the biological role and clinical biomarker potential
of this protein.
■ CONCLUSIONS
Aﬃmers are attractive alternatives to antibodies for binding
target proteins with high aﬃnity and speciﬁcity. Their
exceptional thermal and chemical stability and the fact that
aﬃmers can be produced easily in bacterial cultures (E. coli) in
a reproducible and scalable manner are clear advantages
toward their use as reagents in clinical and bioanalytical assays.
In our study we showed the application of aﬃmers in an LC−
MS-based method for the quantiﬁcation of the low-abundant
biomarker sRAGE in human serum. The novel method was
validated according to EMA and FDA guidelines and enabled
the quantiﬁcation of serum sRAGE at clinically relevant levels
between 0.2 and 10 ng/mL. Moreover, the method showed
good correlation with a previously developed, fully validated,
antibody-based LC−MS method for serum sRAGE quantiﬁ-
cation, although 25% lower sRAGE levels were reported by the
aﬃmer-based method. In conclusion, aﬃmers are small and
versatile aﬃnity ligands with signiﬁcant potential for
biomedical applications as alternatives to antibodies.
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